ArticleFrontiers in cardiovascular medicine2025
Identification of arachidonic acid metabolism-related diagnostic markers in heart failure based on bioinformatics analysis and machine learning.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A bibliometric analysis of artificial intelligence applications in heart failure.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) represents the terminal phase of multiple cardiovascular conditions and is associated with significant morbidity and mortality rates. Arachidonic acid (AA), an essential fatty acid, plays a crucial role in modulating cardiovascular function under both normal and disease states. The purpose of this research was to examine how AA is related to HF, providing new perspective for individualized treatment. Methods: Transcriptomic datasets were retrieved from the Gene Expression Omnibus (GEO) database. The raw data were consolidated to identify differentially expressed genes (DEGs) and subsequently subjected to bioinformatics analysis. Gene ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed. Signature genes were identified through Least Absolute Shrinkage and Selection Operator (LASSO) regression, Support Vector Machine-Recursive Feature Elimination (SVM-RFE), and Random Forest (RF) algorithms. Receiver Operating Characteristic (ROC) curves were generated for gene evaluation, and a nomogram was developed. An analysis of immune cell infiltration was conducted using Single Sample Gene Set Enrichment Analysis (ssGSEA), and Gene Set Enrichment Analysis (GSEA) was conducted to determine important pathways. Subsequently, we also performed drug sensitivity evaluation. Finally, the expression levels of the identified signature genes in HF samples were confirmed using qRT-PCR analysis. Results: Four characteristic genes demonstrating favorable performance in the ROC analysis. The comprehensive nomogram developed in this study exhibited enhanced clinical utility. In addition, notable variations in immune cell infiltration levels were detected, and GSEA highlighted key biological pathways. Conclusion: This investigation demonstrated a strong association between arachidonic acid-associated gene expression and heightened risk of HF, offering novel perspectives on the disease's underlying pathological processes and providing potential insights for personalized management of HF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.